Cytogenetic identification of chromosome abnormalities has become essential for the clinical management of patients with leukemia, and it is currently used to help classify patients into risk groups. With the development of novel genomics technologies, such as Next-Generation Sequencing, numerous new mutations and gene expression signatures have been identified. These breakthroughs allow us to better understand the molecular heterogeneity of hematologic diseases and to better stratify and assess risk for cancer patients. Using these molecular tools, it has become evident that leukemias, lymphomas, and hematologic diseases are characterized by a remarkable genetic heterogeneity, with individual patients presenting distinct and almost unique combinations of chromosome changes and somatically acquired gene mutations. LabPMM offers comprehensive NGS gene panels for AML and other hematological malignancies. Our MyAML® and MyHEME® cancer panels are designed to analyze and interpret sequence information in genes known or suspected to be involved in AML and other hematologic diseases, respectively. These comprehensive assays are capable of detecting single nucleotide substitutions, insertions, deletions, and gene rearrangements. The MyAML and MyHEME cancer panels are aimed at promoting a further understanding of patients’ clinical responses and outcomes. Furthermore, our MyMRD® panel was designed to sensitively capture all classes of variants identified in a precisely defined set of targets that commonly drive myeloid malignancies including AML, MPN, and MDS . Panels run at the time of diagnosis identify both clinically- actionable driver mutations associated with the primary tumor, as well as the subclonal architecture that may be present. Temporal specimens collected and tested during the course of treatment identify the loss or elimination of driver mutations, as well as emergence or re-emergence of new clones and new potential therapeutic targets. NGS Cancer Panels LabPMM Services Catalog 2019 | 55 54